Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation
Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
AmMax Bio, a private clinical-stage biopharmaceutical company developing an innovative portfolio of antibody-drug conjugates (ADC) in oncology, and Lonza, the world’s leading contract development...
FDA Approves Pivekimab Sunirine as First Outpatient ADC for the Treatment of Ultra-Rare Hematologic...
In a landmark advancement for patients with ultra-rare blood cancers, the U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine (Decnupaz™; AbbVie), previously known as IMGN632, marking the first and only antibody-drug conjugate (ADC) authorized for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible...
Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy
Piramal Pharma Solutions Unveils Advanced Payload-Linker Suite in Michigan, Deepening U.S. Innovation Commitment
Piramal Pharma Solutions (PPS) has announced the launch of a state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan, drug-substance facility. This new...
Bristol Myers Squibb Enters Licensing Deal with Lonza for SYNtecan™ ADC Platform
Lonza, a global leader in contract development and manufacturing, has announced an exclusive single-target licensing agreement with Bristol Myers Squibb (BMS) for its proprietary SYNtecan™ linker-payload platform*. This agreement marks a significant milestone in advancing next-generation antibody-drug conjugate (ADC) therapeutics for oncology and other serious diseases.
Pfizer Halts Early ISAC Program Amid Oncology Portfolio Evolution
Pfizer has discontinued development of its early-stage immune-stimulating antibody conjugate (ISAC) PF-08046037, an investigational therapy targeting PD-L1, as part of a strategic realignment of its oncology pipeline. The decision, described as being for 'strategic business reasons' and not due to safety or efficacy concerns, comes after a series of notable clinical successes and high-profile deals that have reshaped Pfizer’s approach to cancer drug development.
Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective...
Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective Cancer Treatment with Focused Local Control
AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company...
AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company History
